CROI 2019 Program and Conference Information

Oral Sessions

75 INTEGRASE (IN) TETRAMERS ARE THE AUTHENTIC TARGETS FOR ALLOSTERIC HIV-1 IN INHIBITORS Pratibha Chowdary Koneru, Nanjie Deng, Ashley Hoyte, Jared Lindenberger, Stephanie Rebensburg, Ashwanth Francis, Dmitry Lyumkis, Alan N. Engelman, Gregory Melikian, Ronald Levy, Mamuka Kvaratskhelia 76 LB TARGETING VIRUS ENV AND CD44 IMPROVES bNAb AVIDITY AND NEUTRALIZATION POTENCY Djin-Ye Oh, Lihong Liu, Jian Yu, Manoj Nair, Manxue Xia, Sho Iketani, Lili Tsai, Yehuda Z. Cohen, Neal Padte, Yaoxing Huang, David Ho Oral Abstract O-07 TB: FROM CONTACT TO CURE AND BEYOND Room 6AB 10:00 AM - 12:00 PM Oral Abstract Moderators Timothy R. Sterling, Vanderbilt University School of Medicine, Nashville, TN, USA Annie F. Luetkemeyer, University of California San Francisco, San Francisco, CA, USA 77 IPT AND PREGNANCY OUTCOMES INHIV-POSITIVEWOMEN, THE TSHEPISO COHORT Nicole Salazar-Austin, Sanjay Lala, Ziyaad Waja, Silvia Cohn, Jennifer Hoffmann, Fildah Mashabela, Christopher Hoffmann, Kelly E. Dooley, Richard E. Chaisson, Neil A. Martinson, for the TSHEPISO Study Team POTENTIAL CONCERN FOR TIMING OF DMPA INJECTION AMONG WOMEN TREATED FOR HIV AND TB Rosie Mngqibisa, Susan E. Cohn, Michelle A. Kendall, Xingye Wu, Kelly E. Dooley, Helen Mcilleron, Jennifer A. Robinson, Cindy Firnhaber, Jhoanna C. Roa, Sharlaa Badal-Faesen, Francis Angira, Mpho S. Raesi, James G. Hakim, Catherine Godfrey, for the A5338 study team IMPROVING CHILD TUBERCULOSIS CONTACTMANAGEMENT IN LESOTHO Yael Hirsch-Moverman, Andrea Howard, Limakatso Lebelo, Koen Frederix, Aprielle Wills, Anneke Hesseling, Joanne E. Mantell, Sharon Nachman, Llang Maama-Maime, Wafaa M. El-Sadr 80 LB SAFETY &PK OFWEEKLY RIFAPENTINE/ISONIAZID (3HP) IN ADULTSWITHHIV ON DOLUTEGRAVIR Kelly E. Dooley, Gavin Churchyard, Radojka M. Savic, Akshay Gupte, Mark A. Marzinke, Nan Zhang, Vinodh Edward, Lisa Wolf, Modulakgotla Sebe, Morongwe Likoti, Mark Fyvie, Innocent Shibambo, Trevor Beattie, Richard E. Chaisson, for the DOLPHIN Study Team 81 LB PHARMACOKINETICS AND SAFETY OF ADJUSTED DARUNAVIR/ RITONAVIRWITH RIFAMPIN IN PLWH Ismaeel Ebrahim, Gary Maartens, Wynand Smythe, Catherine Orrell, Lubbe Wiesner, Helen Mcilleron 82 EARLY BACTERICIDAL ACTIVITY OF HIGH-DOSE ISONIAZID AGAINSTMULTIDRUG-RESISTANT TB Kelly E. Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, Xin Sun, Richard Hafner, Susan L. Rosenkranz, Eric Nuermberger, Laura E. Moran, Kathleen Donahue, Susan Swindells, Andreas H. Diacon, for the ACTG A5312 Study Team 11:45 10:00 10:15 10:30 10:45 11:00 11:15 11:30 78 79 LONG-TERMMORTALITY AFTER TUBERCULOSIS CURE IN THE CIPRA HT-001 TRIAL Yvetot Joseph, Marc Antoine Jean Juste, Serena Koenig, Sean Collins, Zhiwen Yao, Akanksha Dua, Pierre Cremieux, Patrice Severe, Daniel Fitzgerald, Jean William Pape 11:30 83

Oral Sessions • Wednesday

CROI 2019 43